<DOC>
	<DOCNO>NCT01777776</DOCNO>
	<brief_summary>To evaluate safety , tolerability efficacy LEE011 LGX818 administer orally patient BRAF mutant melanoma .</brief_summary>
	<brief_title>Safety Efficacy LEE011 LGX818 Patients With BRAF Mutant Melanoma .</brief_title>
	<detailed_description>In response development treatment melanoma , sponsor review data ongoing study decide halt enrollment patient Phase Ib part study . Consequently , Phase II part study perform . Early termination study due safety concern .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Age ≥18 year . Diagnosis locally advance metastatic melanoma along write documentation BRAF V600 mutation . ECOG performance status 0 2 . Patients enrol Phase Ib must evidence evaluable and/or measurable disease determine RECIST v1.1 . Patients enrol Phase II ( BRAFi naïve resistant ) must evidence measurable disease determine RECIST v1.1 . Archival tumor tissue must obtain patient enrol Phase Ib Phase II arm 1a/b BRAFi naïve patient . If archival tumor tissue available , fresh tumor sample acceptable . For patient enrolled phase II arm 2 , patient must agree undergo fresh tumor biopsy unless one collect prior study entry time disease relapse recent BRAFi treatment . Symptomatic brain metastasis . Symptomatic untreated leptomeningeal disease . Patients inadequate laboratory value screen . In phase II BRAFi naïve arm ( 1a/b ) , prior exposure CDK4/6 inhibitor ( e.g. , PD 0332991 ) Impaired cardiac function clinically significant cardiac disease . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption LEE011 LGX818 . Patients concurrent severe and/or uncontrolled concurrent medical condition . Previous concurrent malignancy . Major surgery &lt; 2 week start study treatment Known diagnosis human immunodeficiency virus ( HIV ) hepatitis C. Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Open-label dose escalation</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>LEE011</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>LGX818</keyword>
	<keyword>RAF kinase inhibitor</keyword>
	<keyword>Metastatic melanoma</keyword>
	<keyword>BRAF</keyword>
	<keyword>V600</keyword>
</DOC>